Recurrent depression, resistant clinician?

Harvard Review of Psychiatry

Volumn 5, Issue 5, 1998, Pages 281-285

  Fredman, Steffany J ^b   Rosenbaum, Jerrold F ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; IMIPRAMINE; LITHIUM; PLACEBO;

BEHAVIOR THERAPY; CLINICAL TRIAL; COGNITIVE THERAPY; DEPRESSION; HUMAN; PRIORITY JOURNAL; PSYCHOTHERAPY; RECURRENT DISEASE; REVIEW;

EID: 0031937147     PISSN: 10673229     EISSN: None     Source Type: Journal    
DOI: 10.3109/10673229809000311     Document Type: Review

References (53)

1. Angst J, Baastrup P, Grof P, Hippius H, Poldinger W, Weis P. The course of monopolar depression and bipolar psychoses. Psychiatr Neurol Neurochir 1973;76:489-500.
2. Consensus Development Panel. NIMH/NIH Consensus Development Conference Statement: mood disorders: pharmacologic prevention of recurrences. Am J Psychiatry 1985;142:469-76.
3. Zis AP, Goodwin FK. Major affective disorder as a recurrent illness: a critical review. Arch Gen Psychiatry 1979;36:835-9.
4. Kupfer DJ. Long-term treatment of depression. J Clin Psychiatry 1991;52(suppl 5):28-34.
5. Fava GA. Holding on: depression, sensitization by antidepressant drugs, and the prodigal experts. Psychother Psychosom 1995;64:57-61.
6. Fava M, Kaji J. Continuation and maintenance treatments of major depressive disorder. Psychiatr Ann 1994;24:281-90.
7. Frank E, Prien RF, Jarrett RB, Keller MB, Kupfer DJ, Lavori PW, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991;48: 851-5.
8. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51:8-19.
9. Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER. The economic burden of depression in 1990. J Clin Psychiatry 1993;54:405-18.
10. Wells KB, Stewart A, Hays RD, Burnam MA, Rogers W, Daniels M, et al. The functioning and well-being of depressed patients: results from the Medical Outcomes Study. JAMA 1989;262:914-9.
11. Keller MB. Depression: a long-term illness. Br J Psychiatry 1994;165(suppl 26):9-15.
12. Angst J, Kupfer DJ, Rosenbaum JF. Recovery from depression: risk or reality? Acta Psychiatr Scand 1996;93:413-9.
13. Greden JF. Maintenance antidepressant treatment. Am Soc Clin Psychopharmacol Prog Notes 1995;6:28-34.
14. Greden JF. Antidepressant maintenance medications: when to discontinue and how to stop. J Clin Psychiatry 1993;54(suppl 8):39-45.
15. Keller MB, Shapiro RW, Lavori PW, Wolfe N. Relapse in major depressive disorder: analysis with the life table. Arch Gen Psychiatry 1982;39:911-5.
16. Gonzales LR, Lewinsohn PM, Clarke GN. Longitudinal follow-up of unipolar depressives: an investigation of predictors of relapse. J Consult Clin Psychol 1985;53:461-9.
17. Keller MB, Lavori PW, Lewis CE, Klerman GL. Predictors of relapse in major depressive disorder. JAMA 1983;250:3299-304.
18. Maj M, Veltro F, Pirozzi R, Lobrace S, Magliano L. Pattern of recurrence of illness after recovery from an episode of major depression: a prospective study. Am J Psychiatry 1992;149: 795-800.
19. Post RM. Mechanisms underlying the evolution of affective disorders: implications for long-term treatment. In: Grunhaus L, Greden JF, eds. Severe depressive disorders. Washington, DC: American Psychiatric Press, 1994:23-65.
20. Prien RF, Kupfer DJ. Continuation drug therapy for major depressive episodes: how long should it be maintained? Am J Psychiatry 1986;143:18-23.
21. Mueller TI, Leon AC, Keller MB, Solomon DA, Endicott J, Warshaw M. Ten-year cumulative probability of recurrence after recovery from an index episode of MDD. Presented at the 150th annual meeting of the American Psychiatric Association, San Diego, California, May 1997.
22. Endicott J, Spitzer RL, Fleiss JL, Cohen J. The Global Assessment Scale: a procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976;33:766-71.
23. Keller MB, Lavori PW, Mueller TI, Endicott J, Coryell W, Hirschfeld RM, et al. Time to recovery, chronicity, and levels of psychopathology in major depression: a 5-year prospective follow-up of 431 subjects. Arch Gen Psychiatry 1992;49:809-16.
24. Keller MB, Lavori PW, Rice J, Coryell W, Hirschfeld RM. The persistent risk of chronicity in recurrent episodes of nonbipolar major depressive disorder: a prospective follow-up. Am J Psychiatry 1986;143:24-8.
25. Harrison W, Rabkin J, Stewart JW, McGrath PJ, Tricamo E, Quitkin F. Phenelzine for chronic depression: a study of continuation treatment. J Clin Psychiatry 1986;47:346-9.
26. Rosenbaum JF, Quitkin FM, Fava M, Amsterdam J, Fawcett J, Zajecka J, et al. Fluoxetine vs. placebo: long-term treatment of MDD. Presented at the 32nd annual meeting of the American College of Neuropsychopharmacology, Maui, Hawaii, December 1993.
27. Doogan DP, Caillard V. Sertraline in the prevention of depression. Br J Psychiatry 1992;160:217-22.
28. Montgomery SA, Dunbar G. Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. Int Clin Psychopharmacol 1993;8:189-95.
29. Duboff EA. Long-term treatment of major depressive disorder with paroxetine. J Clin Psychopharmacol 1993;13(suppl 2): 28S-33S.
30. Anton SF, Robinson DS, Roberts DL, Kensler TT, English PA, Archibald DG. Long-term treatment of depression with nefazodone. Psychopharmacol Bull 1994;30:165-9.
31. Loonen AJ, Peer PG, Zwanikken GJ. Continuation and maintenance therapy with antidepressant agents: meta-analysis of research. Pharm Weekbl [Sci] 1991;13:167-75.
32. Peselow ED, Filippi AM, Goodnick P, Barouche F, Fieve RR. The short- and long-term efficacy of paroxetine HCl, B: Data from a double-blind crossover study and from a year-long term trial vs. imipramine and placebo. Psychopharmacol Bull 1989;25:272-6.
33. Montgomery SA, Dufour H, Brion S, Gailledreau J, Laqueille X, Ferrey G, et al. The prophylactic efficacy of fluoxetine in unipolar depression. Br J Psychiatry 1988;153(suppl 3):69-76.
34. Robert P, Montgomery SA. Citalopram in doses of 20-60 mg is effective in depression relapse prevention: a placebo-controlled 6 month study. Int Clin Psychopharmacol 1995;10(suppl 1):29-35.
35. Frank E, Kupfer DJ, Perel JM, Cornes C, Jarrett DB, Mallinger AG, et al. Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990; 47:1093-9.
36. Kupfer DJ, Frank E, Perel JM, Cornes C, Mallinger AG, Thase ME, et al. Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1992;49:769-73.
37. Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 1996;19:179-200.
38. Thase ME, Simons AD, McGeary J, Cahalane JF, Hughes C, Harden T, et al. Relapse after cognitive behavior therapy of depression: potential implications for longer courses of treatment. Am J Psychiatry 1992;149:1046-52.
39. Thase ME, Simons AD. Cognitive behavior therapy and relapse of nonbipolar depression: parallels with pharmacotherapy. Psychopharmacol Bull 1992;28:117-22.
40. Faravelli C, Ambonetti A, Pallanti S, Pazzagli A. Depressive relapses and incomplete recovery from index episode. Am J Psychiatry 1986;143:888-91.
41. Simons AD, Murphy GE, Levine JL, Wetzel RD. Cognitive therapy and pharmacotherapy for depression: sustained improvement over one year. Arch Gen Psychiatry 1986;43:43-8.
42. Mintz J, Mintz LI, Arruda MJ, Hwang SS. Treatments of depression and the functional capacity to work. Arch Gen Psychiatry 1992;49:761-8.
43. Fawcett J, Scheftner WA, Fogg L, Clarke DC, Young MA, Hedeker D, et al. Time-related predictors of suicide in major affective disorder. Am J Psychiatry 1990;147:1189-94.
44. Frank E, Kupfer DJ, Perel JM, Cornes C, Mallinger AG, Thase ME, et al. Comparison of full-dose versus half-dose pharmacotherapy in the maintenance treatment of recurrent depression. J Affect Disord 1993;27:139-45.
45. Peselow ED, Difiglia C, Fieve RR. Relationship of dose to antidepressant prophylactic efficacy. Acta Psychiatr Scand 1991;84:571-1.
46. Kocsis JH, Friedman RA, Markowitz JC, Leon AC, Miller NL, Gniwesch L, et al. Maintenance therapy for chronic depression: a controlled clinical trial of desipramine. Arch Gen Psychiatry 1996;53:769-74.
47. Herman GL, Weissman MM, Rounsaville BJ, eds. Interpersonal psychotherapy of depression. New York: Basic, 1984.
48. Robinson DS, Lerfald SC, Bennett B, Laux D, Devereaux E, Kayser A, et al. Continuation and maintenance treatment of major depression with the monoamine oxidase inhibitor phenelzine: a double-blind placebo-controlled discontinuation study. Psychopharmacol Bull 1991;27:31-9.
49. Georgotas A, McCue RE, Cooper TB. A placebo-controlled comparison of nortriptyline and phenelzine in maintenance therapy of elderly depressed patients. Arch Gen Psychiatry 1989;46:783-6.
50. Beck AT, Rush AJ, Shaw BF, Emery G. Cognitive therapy of depression. New York: Guilford, 1979.
51. Evans MD, Hollon SD, DeRubeis RJ, Piasecki JM, Grove WM, Garvey MJ, et al. Differential relapse following cognitive therapy and pharmacotherapy for depression. Arch Gen Psychiatry 1992;49:802-8.
52. Fava GA, Grandi S, Zielezny M, Canestrari R, Morphy MA. Cognitive behavioral treatment of residual symptoms in primary major depressive disorder. Am J Psychiatry 1994;151: 1295-9.
53. Pava JA, Fava M, Levenson JA. Integrating cognitive therapy and pharmacotherapy in the treatment and prophylaxis of depression: a novel approach. Psychother Psychosom 1994;61:211-9.